ASTRAZENECA (Gothenburg/Södertälje/Mölndal)

Status: Public (Nasdaq: AZN) | Swedish Employees: ~12,000 | Market Cap: ~$210B

Global biopharmaceutical giant with Swedish R&D center in Mölndal (small molecules). Extensive oncology/immunology biologics portfolio including ADCs (Enhertu, Padcev), checkpoint inhibitors (Imfinzi, Tremelimumab), and bispecifics. Södertälje site designated "global launch facility" for biologics manufacturing with $135M expansion for 50% increased biologics prefilled syringe capacity (operational 2027). BioVentureHub(Gothenburg) nonprofit innovation hub hosts 40+ emerging companies. OligoNova platform partnership with University of Gothenburg for oligonucleotide therapeutics.

SWEDISH ORPHAN BIOVITRUM (SOBI) (Stockholm)

Status: Public (Nasdaq Stockholm: SOBI) | Employees: 1,800 | Revenue: SEK 26B ($2.7B, 2024) | Market Cap:~$10.5B

International rare disease biopharmaceutical specialist. Haematology products: Elocta/Eloctate (rFVIII-Fc hemophilia A), Alprolix (rFIX-Fc hemophilia B), Altuvoct (launched 2024). Immunology: Kineret (anakinra, IL-1R antagonist), Gamifant (emapalumab for primary HLH). Specialty: Synagis (palivizumab, RSV), Beyfortus royalties (25-35% US sales), Doptelet, Zynlonta, Vonjo. Pipeline: SEL-212 (chronic refractory gout, SEK 2-5B peak sales potential); Aspaveli (C3G/IC-MPGN, EC approved January 2026). December 2025 announced Arthrosi Therapeutics acquisition. 30+ CDMO partners globally.

BIOARCTIC AB (Stockholm)

Status: Public (Nasdaq Stockholm: BIOA B) | Founded: 2003 | Stock: SEK 320+

Research-based biopharma focused on neurodegenerative disease-modifying treatments. Lecanemab (Leqembi®) humanized anti-Aβ protofibril IgG1 antibody for Alzheimer's disease - approved in 51 countries including US, Japan, China, UK. FDA-approved IV maintenance dosing (January 2025) and subcutaneous autoinjector LEQEMBI IQLIK (August 2025). Partnerships with Eisai (global development since 2007) and Biogen (co-commercialisation since 2014). Stock up 128% in 2022 following positive Clarity AD Phase 3.

ALZECURE PHARMA AB (Huddinge)

Status: Public (Nasdaq First North: ALZCUR) | Karolinska Institutet spinout focused on neurodegenerative/pain treatments using NeuroRestore and Painless platforms.

ALLIGATOR BIOSCIENCE AB (Lund)

Status: Public (Nasdaq Stockholm: ATORX) | Founded: 2000 | Market Cap: ~$8.7M

Clinical-stage immuno-oncology antibody developer. Mitazalimab (CD40 agonist) Phase 3-ready following unprecedented 18-month survival data in OPTIMIZE-1 trial (metastatic pancreatic cancer). ALLIGATOR-GOLD human antibody library and RUBY bispecific format platforms. Partnerships with Aptevo, MacroGenics, Orion, Shanghai Henlius.

BIOINVENT INTERNATIONAL AB (Lund)

Status: Public (Nasdaq Stockholm: BINV) | Founded: 1997

Antibody-based immuno-oncology with proprietary n-CoDeR library (30+ billion human antibody genes). BI-1206(anti-FcγRIIB) Phase 1/2a; BI-1808 (anti-TNFR2) Phase 1/2a; BT-001 (CTLA-4 oncolytic virus with Transgene). MSD/Merck clinical collaboration (2024).

CANTARGIA AB (Lund)

Status: Public (Nasdaq Stockholm: CANTA) | Founded: 2010 | Stock: ~SEK 4.09

Antibody developer targeting IL1RAP for cancer and autoimmune diseases. Nadunolimab (CAN04) Phase 2a for pancreatic cancer, NSCLC - dual mechanism blocking tumour inflammation and stimulating immune-mediated elimination. CAN10 Phase 1 for autoimmune diseases.

MENDUS AB (Stockholm/Gothenburg)

Status: Public (Nasdaq Stockholm: IMMU) | Immuno-oncology cell therapy company. DCP-001 allogeneic dendritic cell vaccine in Phase 2 ADVANCE-II for AML maintenance, Phase 1 ALISON for ovarian cancer. Manufacturing capabilities from lab to commercial scale.

HANSA BIOPHARMA AB (Lund)

Status: Public (Nasdaq Stockholm: HNSA) | Stock: ~SEK 31.24

Commercial-stage developing IgG-cleaving enzyme therapies. Imlifidase (IDEFIRIX®) first-in-class enzyme conditionally approved in Europe for kidney transplant desensitization. US BLA submitted December 2025 following positive Phase 3 ConfIdeS results (eGFR 51.5 vs 19.3, p<0.0001). 5-year follow-up: 90% patient survival. Gene therapy enabling collaborations with Genethon and Sarepta for pre-treatment in gene therapies. Next-gen HNSA-5487 with redosing potential in Phase 1.

CALLIDITAS THERAPEUTICS AB (Stockholm)

Status: Public (Nasdaq: CALT, Stockholm: CALTX) | TARPEYO®/Kinpeygo® first FDA-approved treatment for IgA nephropathy. Full approval December 2023 based on NefIgArd Phase 3 demonstrating eGFR benefit 5.05 mL/min/1.73m² vs placebo. STADA partnership for EU commercialization.

ANOCCA AB (Södertälje)

Status: Private | Founded: 2014 | Clinical-stage TCR-T cell therapy developer targeting KRAS mutations in pancreatic cancer. Nordic's largest GMP-certified cell therapy manufacturing facility licensed 2024. €25M EIB venture debt (2024), partnerships with EmendoBio and MaxCyte.

NEXTCELL PHARMA AB (Huddinge)

Status: Public (Nasdaq First North: NXTCL) | ProTrans allogeneic MSC therapy for Type 1 diabetes - 6-year follow-up shows sustained C-peptide preservation. Cellaviva Scandinavia's largest private stem cell bank.

NORTHX BIOLOGICS AB (Matfors/Stockholm)

Status: Private (Flerie Invest-led) | Website: nxbio.com

GMP manufacturing for advanced biologics: pDNA, mRNA, recombinant proteins, viral vectors, cell therapies, outer membrane vesicles. 7,000m² facility, 30+ years GMP experience. Designated Swedish national innovation hub for advanced therapeutics (Vinnova-supported). Clients include Mendus, Abera Bioscience, Amarna Therapeutics.

RECIPHARM AB (Stockholm)

Status: Private (EQT IX since 2021) | Employees: ~9,000 | Revenue: SEK 14.7B ($1.4B)

4th largest global CDMO with end-to-end services. ReciBioPharm division for nucleic acids, microbiome, viruses. 2022 acquisitions: Vibalogics (CGT), GenIbet (biologics), Arranta Bio (microbiome, mRNA). Swedish facilities in Höganäs, Karlskoga, Solna, Uppsala.

CYTIVA (Uppsala/Umeå)

Status: Danaher Corporation subsidiary (acquired 2020 for $21.4B) | Swedish Employees: 1,200-1,300 (Uppsala), ~450 (Umeå)

World leader in bioprocessing technologies rooted in Pharmacia heritage (Nobel Prize research). Products include Sephadex, Sepharose, MabSelect, Capto resins; ÄKTA purification; single-use FlexFactory; HyClone media; Biacore SPR; Sefia/Sepax/Xuri cell therapy; KUBio modular facilities. Uppsala hosts one of world's largest chromatography resin manufacturing facilities, 75%+ of FDA-approved biologics (2019) used Cytiva technologies. Uppsala University strategic partnership (2024).

TESTA CENTER (Uppsala)

Founded: 2018 | National testbed for biomanufacturing on Cytiva premises. 2,500m² non-GMP pilot-scale facility with four bioprocessing labs. ~EUR 10M Vinnova funding, ~EUR 4.5M Cytiva investment.

ATLAS ANTIBODIES AB (Stockholm)

Ownership: Patricia Industries (Investor AB) | Products: 22,000+ validated antibodies from Human Protein Atlas project, PrecisA Monoclonals, MolBoolean technology. Global distribution including Sigma-Aldrich.

GENOVIS AB (Kävlinge)

Status: Public (Nasdaq First North) | SmartEnzymes for biologics characterization: FabRICATOR, GlycINATOR, GlyCLICK. Applications across mAb, ADC, biosimilar QC. Waters Corporation partnership. SwedenBIO Award 2023.